Vertex announces casgevy™ reimbursement agreement for the treatment of transfusion-dependent beta thalassemia in england

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) announced today a reimbursement agreement with nhs england for eligible transfusion-dependent beta thalassemia (tdt) patients to access the crispr/cas9 gene-edited therapy, casgevy™ (exagamglogene autotemcel), from today. the reimbursement agreement comes as the national institute for health and care excellence (nice) issues positive guidance recommending casgevy's use in the nhs. the united kingdom (u.k.) medicines and healthcare p.
VRTX Ratings Summary
VRTX Quant Ranking